Effect of Functional milk product On the Metabolic Syndrome II

Submission date	Recruitment status	Prospectively registered
18/12/2007	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
05/02/2008	Completed	Results
Last Edited	Condition category	Individual participant data
05/02/2008	Nutritional, Metabolic, Endocrine	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Juergen Schrezenmeir

Contact details

Institute for Physiology and Biochemistry of Nutrition Federal Reserach Centre for Nutrition and Food Hermann-Weigmann-Str. 1 Kiel Germany 24103 +49 (0)431 609 2220 juergen.schrezenmeir@bfel.de

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

Randomised, controlled, double-blind clinical study on the effect of a functional milk-product on metabolism of men with diagnosed metabolic syndrome: study with extended sample size

Acronym

EFOMS II

Study objectives

The goal of the investigation is the question, to what extent the risk of the metabolic syndrome may be reduced by substances naturally occurring in milk. The pathophysiology of the metabolic syndrome is characterised by an insulin resistance, a dyslipidaemia, an essential hypertension and adiposity of the central type and frequently leads to early manifestation of type 2 diabetes mellitus and atherosclerosis. Such metabolic disturbances increase in the industrialised countries and in the developing countries, too, and represent an important economical and public-health cost factor. It is necessary to identify the relevant factors of human nutrition and to develop potential avoidance strategies, e.g. by development of functional food.

The cow-milk derived substances, which will be used in this study have had influenced individual components of the metabolic syndrome and lowered the risk of components of the metabolic syndrome in own animal and human trials.

This study is an extension of a previous human study (ISRCTN41474531 - see http://www.controlled-trials.com/ISRCTN41474531).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Ethics Committee of the Medical Faculty of the Christian-Albrechts-University of Kiel (Germany) on the 26th October 2007 (ref: A171/06 - extended sample size).

Study design

The study is a randomised double-blind placebo-controlled intervention study over 8 weeks.

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Metabolic syndrome

Interventions

The volunteers of the verum group will take one portion of the functional milk-product (product code 966125, a non-registered product) once a day after lunch with a dessert for 56 days. The product of the control group is based on meat protein and is isoenergetic and isonitrogenous.

Primary and secondary outcome measures will be analysed before and at the end of the intervention.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Functional milk-product (product code 966125, a non-registered product)

Primary outcome(s)

Change of HOMeostasis model Assessment of Insulin Resistance (HOMA-IR) during the intervention period.

Key secondary outcome(s))

- 1. Blood pressure
- 2. Body mass index (BMI), waist-to-hip ratio
- 3. Mean blood glucose during continuously glucose monitoring
- 4. Postprandial concentration of several hormones and blood parameters linked mainly to carbohydrate metabolism

Completion date

30/07/2008

Eligibility

Key inclusion criteria

- 1. Men. 45 70 years old
- 2. A metabolic syndrome as defined by the International Diabetes Federation, 2006 (A new IDF worldwide definition of the metabolic syndrome: the rationale and the results Diabetes Voice, Vol. 50 Issue 3, 2005)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

- 1. Participation in a clinical study with a medicament or a medicinal product within the last 30 days or simultaneous participation in another clinical examination
- 2. Intake of nitrate and/or calcium antagonists and/or alpha-blockers, which affect the blood pressure
- 3. Known metabolic or gastro-intestinal diseases, which affects the absorption, metabolism or excretion of food or food components
- 4. Condition after operation of the gastro-intestinal tract, which affect gastro-intestinal motility
- 5. Haemoglobin less than 12 g/dL
- 6. Malfunction of blood coagulation or drugs, leading to malfunction of blood coagulating

diabetes

- 7. Operation within the last 3 months, which still affects the current state of health
- 8. Illness of thyroid gland, which has metabolic and/or cardiovascular effects
- 9. Known hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection or chronic liver damage
- 10. Kidney insufficiency
- 11. Hypercalcaemia
- 12. Drug or alcohol abuse
- 13. Intake of drugs affecting the absorption, metabolism or excretion of food components or the gastro-intestinal tract
- 14. Intake of hormone preparations
- 15. Vegetarianism, anorexia, bulimia
- 16. Known milk protein allergy

Date of first enrolment

27/11/2007

Date of final enrolment

30/07/2008

Locations

Countries of recruitment

Germany

Study participating centre Institute for Physiology and Biochemistry of Nutrition

Kiel Germany 24103

Sponsor information

Organisation

Humana GmbH (Germany)

Funder(s)

Funder type

Industry

Funder Name

Humana GmbH (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration